Sequoia Financial Advisors LLC Acquires 195 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Sequoia Financial Advisors LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 32.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 798 shares of the company’s stock after purchasing an additional 195 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Medpace were worth $266,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Suncoast Equity Management lifted its position in shares of Medpace by 4.8% in the 3rd quarter. Suncoast Equity Management now owns 1,652 shares of the company’s stock worth $551,000 after acquiring an additional 75 shares during the period. Allspring Global Investments Holdings LLC lifted its position in shares of Medpace by 31.3% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 153,156 shares of the company’s stock worth $51,123,000 after acquiring an additional 36,473 shares during the period. Raymond James & Associates lifted its position in shares of Medpace by 1.7% in the 3rd quarter. Raymond James & Associates now owns 55,689 shares of the company’s stock worth $18,589,000 after acquiring an additional 954 shares during the period. Blue Trust Inc. lifted its position in shares of Medpace by 18.5% in the 3rd quarter. Blue Trust Inc. now owns 665 shares of the company’s stock worth $222,000 after acquiring an additional 104 shares during the period. Finally, nVerses Capital LLC lifted its position in shares of Medpace by 50.0% in the 3rd quarter. nVerses Capital LLC now owns 1,200 shares of the company’s stock worth $401,000 after acquiring an additional 400 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Down 0.3 %

Shares of Medpace stock opened at $329.35 on Tuesday. Medpace Holdings, Inc. has a 12 month low of $239.00 and a 12 month high of $459.77. The business has a fifty day simple moving average of $351.45 and a 200 day simple moving average of $381.00. The stock has a market cap of $10.20 billion, a PE ratio of 34.03, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.24. Medpace had a return on equity of 50.87% and a net margin of 17.66%. The business had revenue of $533.32 million during the quarter, compared to analysts’ expectations of $540.99 million. During the same period in the previous year, the firm earned $2.22 earnings per share. The firm’s quarterly revenue was up 8.3% compared to the same quarter last year. Analysts expect that Medpace Holdings, Inc. will post 11.77 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on MEDP shares. TD Cowen dropped their target price on Medpace from $413.00 to $372.00 and set a “buy” rating for the company in a report on Wednesday, October 23rd. Robert W. Baird downgraded Medpace from an “outperform” rating to a “neutral” rating and cut their target price for the stock from $413.00 to $349.00 in a research report on Wednesday, October 23rd. Jefferies Financial Group downgraded Medpace from a “buy” rating to a “hold” rating and cut their price objective for the company from $415.00 to $345.00 in a research report on Wednesday, September 25th. Redburn Atlantic assumed coverage on Medpace in a research report on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective for the company. Finally, StockNews.com downgraded Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and a consensus price target of $380.00.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.